[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

701. Experimental Transplantation - Basic Biology, Engraftment and Disease Activity: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 10, 2011: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)
Evidence for the Involvement of CXCR4 Signaling in In Vivo Self-Renewal of Transplanted Hematopoietic Stem Cells

Chen-YI LAI1*, Makoto Otsu, MD, PhD1*, Motohito Okabe1*, Sachie Suzuki, M.D.1*, Satoshi Yamazaki1,2*, Masafumi Onodera, M.D., Ph.D.3*, Hideo Ema, M.D., Ph.D.1, Shigeru Kakuta, Ph.D.4*, Yoichiro Iwakura, PhD4* and Hiromitsu Nakauchi, MD, PhD1,2*

1Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Nakauchi Stem Cell and Organ Regeneration Project, Exploratory Research for Advanced Technology, Japan Science Technology, Tokyo, Japan
3Department of Genetics, National Research Institute for Child Health and Development, Tokyo, Japan
4Division of Cell Biology, Center for Experimental Medicine , Institute of Medical Science, University of Tokyo , Tokyo, Japan

Impairment of Hematopoietic Stem Cell (HSC) Niche by G-CSF Is Associated with Rapid Mobilization of Serially Reconstituting HSC and Reduced Competitive Repopulation of Mobilized Bone Marrow

Jean-Pierre Levesque, PhD, Valerie Barbier*, Bianca Nowlan*, Domenica McCarhty* and Ingrid G Winkler, PhD*

Mater Medical Research Institute, South Brisbane, Australia

Tracking Reconstitution Dynamics in Mice Co-Transplanted with Hematopoietic Stem Cells From Nine Distinguishable Donor Types

Brad Dykstra, PhD1*, Sulima Geerman1*, Jaring Schreuder1*, Martha Ritsema1* and Gerald De Haan, PhD2

1Stem Cell Biology, University Medical Center Groningen, Groningen, Netherlands
2University of Groningen, Groningen, Netherlands

Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers

Brian Kornblit, MD, PhD1*, Billanna Hwang1*, Barry Storer, PhD1*, Monica S Thakar, MD1, Erlinda B Santos1*, Richard A. Nash, MD2 and Brenda M. Sandmaier, MD2

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

Distinct Human Cell Populations Produce Rapidly Detectable Levels of Neutrophils and Platelets in NOD/SCID-IL-2Receptor Gamma Chain Null Mice Transgenically Engineered to Produce Human Myeloid Growth Factors

Paul H. Miller*, Alice M.S. Cheung, PhD*, Suzan Imren, MD*, Philip A Beer, BM, MRCP, MRCPath*, Shabnam Rostamirad*, Kiran Dhillon*, R. Keith Humphries, MD, PhD and Connie J. Eaves, PhD

Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada

Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34+/CD38low Cells One Year Following Autologous Stem Cell Transplantation

Carolien M Woolthuis1*, Annet Z Vos2*, Gerwin Huls1*, Joost TM de Wolf2*, Jan J. Schuringa, PhD1 and Edo Vellenga, PhD3

1Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
2Hematology, University Medical Center Groningen, Groningen, Netherlands
3Hematology, University Medical Center Groningen UMCG, Groningen, Netherlands

Lack of CD34 Expression in Acute Myeloid Leukemia (AML) Is a Favorable Prognostic Factor in Patients Treated with Stem Cell Transplant Irrespective of the Cytogenetic Risk

Fahed Almhareb, MBBS, FACP1, Claudia Ulrike Walter, PhD2*, Randa Nounou, M.D.2*, Salem Khalil, M.D.2*, Nasir Bakshi, M.D.2, Tarek Owaidah, MD, FRCPA2, Naeem A. Chaudhri, MD, FACP1, Hazzaa Al Zahrani, M.D.1*, Said Mohamed, M.D.1*, Walid Rasheed, M.D.1*, Fahad Alsharif, M.D.1, Mahmoud Aljurf, M.D.1 and Maher Albitar, M.D.2

1Oncology Center , King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
2Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

*signifies non-member of ASH